FDA
-
-
-
-
-
-
-
Zevra Reports Full Year 2024 and Fourth Quarter Financial Results
-
-
-
-
-
-
-
Zevra Therapeutics, Inc. (ZVRA) PT Raised to $21 at Roth/MKM
-
-
-
-
-
-
-
FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C
-
-
-
-
-
-
-
William Blair Starts Zevra Therapeutics, Inc. (ZVRA) at Outperform
-
-
-
-
-
-
-
Zevra Therapeutics to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest
-
-
-
-
-
-
-
Zevra Announces Board of Directors and Leadership Changes
-
-
-
-
-
-
-
Zevra Therapeutics Appoints Biopharma Veteran Wendy Dixon, Ph.D., to Board of Directors
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

